RSV Vaccines
Recombinant protein and mRNA vaccines
This page catalogs 3 respiratory syncytial virus (RSV) vaccine products. RSV vaccines represent one of the newest categories in the licensed vaccine portfolio, with all three products receiving FDA approval in 2023–2024 after decades of research setbacks following a failed 1960s formalin-inactivated RSV vaccine candidate.
Last updated: April 2026.
RSV Vaccine Catalog
| Trade Name | Generic Designation | Manufacturer | Vaccine Type | Regulatory Status & Year | Key Notes |
|---|---|---|---|---|---|
| Abrysvo | RSV vaccine (bivalent, prefusion F) | Pfizer | Recombinant protein subunit | FDA Licensed, 2023 | Maternal and older adult indication |
| Arexvy | RSV vaccine (adjuvanted) | GSK | Recombinant + AS01 adjuvant | FDA Licensed, 2023 | Adults ≥60y |
| mRESVIA | RSV vaccine (mRNA) | Moderna | mRNA | FDA Licensed, 2024 | First mRNA RSV vaccine; adults ≥60y |
Sources
Regulatory data sourced from FDA CBER Vaccines Licensed for Use in the United States (March 2026). Catalog scope informed by Khan, Shaz, The Ultimate Vaccine Timeline.